title: Cellular and gene therapy for major histocompatibility complex class II deficiency.
abstract: Major histocompatibility complex (MHC) class II deficiency is a primary immunodeficiency. Lentiviral vectors are used for gene therapy in a mouse model of this disease. In addition, by a direct genetic correction approach, a diagnostic test to determine which of the four MHC II genes is defective in new MHC II-deficiency patients has been optimized.
authors.affiliation: Immunology and Transplant Unit, Division of Immunology and Allergology, Geneva University Hospital, 1211 Geneva 4, Switzerland.
authors.forename: Franck
authors.initials: F
authors.lastname: Matheux
authors.forename: Jean
authors.initials: J
authors.lastname: Villard
mesh_terms: D000818:Animals; D015316:Genetic Therapy; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D006801:Humans; D016511:Severe Combined Immunodeficiency / Q000235:genetics* / Q000628:therapy*
chemical_list: D000949:Histocompatibility Antigens Class II